{
    "title": "Biomarker Discovery with Quantum Neural Networks: A Case-study in CTLA4-Activation Pathways. (arXiv:2306.01745v1 [q-bio.QM])",
    "abstract": "Biomarker discovery is a challenging task due to the massive search space. Quantum computing and quantum Artificial Intelligence (quantum AI) can be used to address the computational problem of biomarker discovery tasks. We propose a Quantum Neural Networks (QNNs) architecture to discover biomarkers for input activation pathways. The Maximum Relevance, Minimum Redundancy (mRMR) criteria is used to score biomarker candidate sets. Our proposed model is economical since the neural solution can be delivered on constrained hardware. We demonstrate the proof of concept on four activation pathways associated with CTLA4, including (1) CTLA4-activation stand-alone, (2) CTLA4-CD8A-CD8B co-activation, (3) CTLA4-CD2 co-activation, and (4) CTLA4-CD2-CD48-CD53-CD58-CD84 co-activation. The model indicates new biomarkers associated with the mutational activation of CLTA4-associated pathways, including 20 genes: CLIC4, CPE, ETS2, FAM107A, GPR116, HYOU1, LCN2, MACF1, MT1G, NAPA, NDUFS5, PAK1, PFN1, PGAP",
    "link": "http://arxiv.org/abs/2306.01745",
    "context": "Title: Biomarker Discovery with Quantum Neural Networks: A Case-study in CTLA4-Activation Pathways. (arXiv:2306.01745v1 [q-bio.QM])\nAbstract: Biomarker discovery is a challenging task due to the massive search space. Quantum computing and quantum Artificial Intelligence (quantum AI) can be used to address the computational problem of biomarker discovery tasks. We propose a Quantum Neural Networks (QNNs) architecture to discover biomarkers for input activation pathways. The Maximum Relevance, Minimum Redundancy (mRMR) criteria is used to score biomarker candidate sets. Our proposed model is economical since the neural solution can be delivered on constrained hardware. We demonstrate the proof of concept on four activation pathways associated with CTLA4, including (1) CTLA4-activation stand-alone, (2) CTLA4-CD8A-CD8B co-activation, (3) CTLA4-CD2 co-activation, and (4) CTLA4-CD2-CD48-CD53-CD58-CD84 co-activation. The model indicates new biomarkers associated with the mutational activation of CLTA4-associated pathways, including 20 genes: CLIC4, CPE, ETS2, FAM107A, GPR116, HYOU1, LCN2, MACF1, MT1G, NAPA, NDUFS5, PAK1, PFN1, PGAP",
    "path": "papers/23/06/2306.01745.json",
    "total_tokens": 1055,
    "translated_title": "利用量子神经网络进行生物标志物的发现：以CTLA4激活通路的案例研究为例",
    "translated_abstract": "生物标志物的发现是一项具有挑战性的任务，由于搜索空间庞大。量子计算和量子人工智能（量子AI）可以用于解决生物标志物发现任务的计算问题。我们提出了一种量子神经网络（QNNs）架构，用于发现输入激活通路的生物标志物。最大相关性，最小冗余（mRMR）标准用于评分生物标志物候选集。由于神经解决方案可以在受限硬件上交付，所以我们提出的模型是经济的。我们在与CTLA4相关的四条激活通路上展示了证明概念，包括（1）CTLA4激活独立，（2）CTLA4-CD8A-CD8B共同激活，（3）CTLA4-CD2共同激活，以及（4）CTLA4-CD2-CD48-CD53-CD58-CD84共同激活。该模型指出与CLTA4相关通路的突变激活有新的生物标志物，包括20个基因：CLIC4，CPE，ETS2，FAM107A，GPR116，HYOU1，LCN2，MACF1，MT1G，NAPA，NDUFS5，PAK1，PFN1，PGAP",
    "tldr": "该论文介绍了一种利用量子神经网络的模型，可以用于发现与CLTA4通路相关的新生物标志物，并且该模型经济实用。",
    "en_tdlr": "This paper presents a Quantum Neural Networks(QNNs) architecture that can be used to discover new biomarkers associated with CLTA4 pathways, and the model is economical since the neural solution can be delivered on constrained hardware."
}